Clock genes in pancreatic disease progression: from circadian regulation to dysfunction.
[BACKGROUND] Circadian rhythms, governed by core clock genes, are essential for maintaining metabolic, endocrine, and immune homeostasis.
APA
Zheng T, Wang K, et al. (2025). Clock genes in pancreatic disease progression: from circadian regulation to dysfunction.. Annals of medicine, 57(1), 2528449. https://doi.org/10.1080/07853890.2025.2528449
MLA
Zheng T, et al.. "Clock genes in pancreatic disease progression: from circadian regulation to dysfunction.." Annals of medicine, vol. 57, no. 1, 2025, pp. 2528449.
PMID
40652400
Abstract
[BACKGROUND] Circadian rhythms, governed by core clock genes, are essential for maintaining metabolic, endocrine, and immune homeostasis. Disruption of these rhythms has been increasingly implicated in the pathogenesis of various pancreatic diseases.
[OBJECTIVE] This review summarizes current evidence on the role of circadian rhythm disruption in pancreatic diseases, including type 2 diabetes (T2D), type 1 diabetes (T1D), pancreatitis, and pancreatic cancer (PC), with a focus on underlying mechanisms involving clock gene dysregulation.
[RECENT FINDINGS] In T2D, dampened oscillations of clock gene expression in pancreatic islets are associated with impaired insulin secretion and loss of cellular synchrony. In T1D, circadian dysregulation enhances immune activation and reduces β-cell tolerance, accelerating disease progression. In pancreatitis, especially in chronic forms, loss of core clock components such as Bmal1 exacerbates pancreatic stellate cell activation, fibrosis, and inflammatory cytokine release. Additionally, circadian disruption has been linked to pancreatic tumorigenesis, suggesting a potential role of clock genes in early cancer development through modulation of the inflammatory microenvironment and stromal remodeling.
[CONCLUSION] Circadian clock genes play a multifaceted role in pancreatic disease pathophysiology, extending beyond metabolic regulation to influence immune responses, inflammation, and tumorigenesis. Understanding these mechanisms may inform the development of novel circadian-based therapeutic strategies for pancreatic disorders.
[OBJECTIVE] This review summarizes current evidence on the role of circadian rhythm disruption in pancreatic diseases, including type 2 diabetes (T2D), type 1 diabetes (T1D), pancreatitis, and pancreatic cancer (PC), with a focus on underlying mechanisms involving clock gene dysregulation.
[RECENT FINDINGS] In T2D, dampened oscillations of clock gene expression in pancreatic islets are associated with impaired insulin secretion and loss of cellular synchrony. In T1D, circadian dysregulation enhances immune activation and reduces β-cell tolerance, accelerating disease progression. In pancreatitis, especially in chronic forms, loss of core clock components such as Bmal1 exacerbates pancreatic stellate cell activation, fibrosis, and inflammatory cytokine release. Additionally, circadian disruption has been linked to pancreatic tumorigenesis, suggesting a potential role of clock genes in early cancer development through modulation of the inflammatory microenvironment and stromal remodeling.
[CONCLUSION] Circadian clock genes play a multifaceted role in pancreatic disease pathophysiology, extending beyond metabolic regulation to influence immune responses, inflammation, and tumorigenesis. Understanding these mechanisms may inform the development of novel circadian-based therapeutic strategies for pancreatic disorders.
MeSH Terms
Humans; Disease Progression; Pancreatic Neoplasms; Circadian Rhythm; Diabetes Mellitus, Type 2; Circadian Clocks; Diabetes Mellitus, Type 1; Animals; Pancreatic Diseases; Pancreatitis; CLOCK Proteins
같은 제1저자의 인용 많은 논문 (5)
- Diagnostic performance and generalizability of a clinical-ultrasound radiomics model for predicting extrathyroidal extension in thyroid carcinoma: a retrospective study.
- State-of-the-art review:Cardiac magnetic resonance imaging in primary cardiac tumors.
- Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis.
- Synergistic inhibitory effects of enzalutamide and its phase I metabolite on UDP-glucuronosyltransferase 1A1 (UGT1A1) and risk prediction of drug-drug interactions.
- Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy.